State of the Nation – A Report into Melanoma
A landmark report provides status of melanoma in Australia, and the the roadmap to achieve zero deaths from melanoma this decade.
Neoadjuvant therapy, a breakthrough in Stage III melanoma treatment
In what is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy, a new study has revealed that drug treatment before surgery is effective in preventing deadly spread of the disease.
MIA joins Sydney Health Partners
MIA has joined Sydney Health Partners, with a shared focus on more rapidly translating research evidence into patient benefit.
Congratulations Dr Hansol Lee
A promising young MIA researcher is conferred with University of Sydney PhD.
Overcoming resistance to immunotherapy
Developing a screening technique to provide clinicians with rationale for selecting a drug treatment regime.
Genes involved in early brain metastasis
Understanding the genes involved in the development of early brain metastases.
Acral and Uveal Melanoma
Identifying genes involved in all melanoma sub-types, to determine the most effective treatment.
The Australian Melanoma Genome Project
Using whole genome sequencing technologies to identify the genetic mutations that cause melanoma, so treatment can be personalised.
Predicting response to immunotherapy
Identifying genes which determine response to immunotherapy, and then determining the signalling pathways these genes are affecting.
Adjuvant Therapy Clinical Trial
MIA is experiencing great success with multi-discipline trials in the neo-adjuvant and adjuvant settings.